Max-40279
/ Maxinovel
- LARVOL DELTA
Home
Next
Prev
1 to 17
Of
17
Go to page
1
November 04, 2025
Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia
(ASH 2025)
- "For ex-vivo sensitivity assays, AML cells were treated with several dilutions of a FLT3i(Sorafenib, Midostaurin, Crenolanib, Quizartinib, Gilteritinib, Tuspetinib and MAX-40279 (a dualFLT3/FGFR inhibitor)) and cell viability was assessed with CellTiter-Glo® (Promega). Using our MS-based proteomics measurements and sensitivity results with our proprietary MLmodel, we processed both AML patient samples (N=57) and patient-derived cell lines (N=59), and wewere able to identify 7 distinct clusters. Previously we demonstrated that RPPA proteomics could discriminate FLT3i sensitive andresistant cases and here we present orthogonal confirmation by MS proteomics and ex-vivo sensitivityassays. Moreover, we show that the expression of only three proteins forms a robust biomarker topredict FLT3i sensitivity of FLT3-MUT AML patients prior to therapy. We also identified AML cell lines thatmimic both FLT3i resistance and sensitivity, and combined with deep proteomics data, these..."
Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD34 • FLT3 • PXN • SMARCA2
June 21, 2022
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=108 | Not yet recruiting | Sponsor: Maxinovel Pty., Ltd.
New P1/2 trial • Oncology • Solid Tumor
May 27, 2022
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
(clinicaltrials.gov)
- P2 | N=30 | Recruiting | Sponsor: Maxinovel Pty., Ltd.
New P2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR1OP2
May 11, 2022
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=28 | Recruiting | Sponsor: Maxinovel Pty., Ltd.
Combination therapy • New P1 trial • Oncology • Solid Tumor • FGFR1OP2
January 19, 2022
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Nov 2021 ➔ Nov 2022
Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • FGFR • FLT3
January 19, 2022
MAX-40279-01 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Nov 2021 ➔ Nov 2022
Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MRI
January 19, 2022
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022
Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
December 11, 2021
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
(clinicaltrials.gov)
- P2; N=130; Not yet recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Oct 2022 ➔ Oct 2023
Clinical • Trial completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • MSI
November 22, 2021
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Colorectal Cancer
(clinicaltrials.gov)
- P2; N=130; Not yet recruiting; Sponsor: Maxinovel Pty., Ltd.
Clinical • New P2 trial • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • MSI
September 29, 2021
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
(clinicaltrials.gov)
- P1/2; N=100; Recruiting; Sponsor: Maxinovel Pty., Ltd.
Clinical • Combination therapy • New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
May 21, 2021
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: May 2021 ➔ Dec 2021; Trial primary completion date: Nov 2020 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • FGFR
May 21, 2021
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Feb 2021 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021
Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
May 21, 2021
MAX-40279-01 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Feb 2021 ➔ Dec 2021; Trial primary completion date: Nov 2020 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
December 05, 2019
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.
Clinical • New P1 trial
December 03, 2019
MAX-40279-01 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.
Clinical • New P1 trial
October 01, 2019
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Dec 2019 ➔ May 2021; Trial primary completion date: Jun 2019 ➔ Nov 2020
Clinical • Trial completion date • Trial primary completion date
January 22, 2019
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
1 to 17
Of
17
Go to page
1